Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 539,960
  • Shares Outstanding, K 91,830
  • Annual Sales, $ 460 K
  • Annual Income, $ -64,120 K
  • 60-Month Beta 1.09
  • Price/Sales 1,178.12
  • Price/Cash Flow N/A
  • Price/Book 4.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.37 +9.50%
on 08/07/19
6.47 -9.12%
on 07/31/19
-0.42 (-6.67%)
since 07/19/19
3-Month
5.37 +9.50%
on 08/07/19
6.81 -13.66%
on 05/21/19
-0.78 (-11.71%)
since 05/20/19
52-Week
5.06 +16.21%
on 10/24/18
7.85 -25.10%
on 01/16/19
+0.61 (+11.57%)
since 08/20/18

Most Recent Stories

More News
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -13.33% and -45.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 5.88 (-1.01%)
Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights

--- Initiating AUDREY(TM) Phase 2/3 clinical study for VOS in Dry Eye Syndrome -

AUPH : 5.88 (-1.01%)
Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUPH : 5.88 (-1.01%)
Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that it will release its second quarter 2019 financial results on Tuesday, August 6, 2019, after the market closes....

AUPH : 5.88 (-1.01%)
Aurinia Announces Further Strengthening of the Senior Management Team

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the "Company"), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis ("LN"), today announced the appointments of...

AUPH : 5.88 (-1.01%)
ACHN : 4.60 (-1.08%)
ILJIN Comments on Aurinia Pharmaceutical's Annual Meeting

ILJIN SNT Co., Ltd. ("ILJIN"), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) ("Aurinia" or the "Corporation"), which together with certain affiliates holds an approximate...

AUPH : 5.88 (-1.01%)
Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting

--Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM

AUPH : 5.88 (-1.01%)
Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

--Proxy voting deadline is 10:00 AM Mountain Time on Monday, June 24th

AUPH : 5.88 (-1.01%)
As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia's Full Potential

SOURCE: ILJIN SNT Co., Ltd.

AUPH : 5.88 (-1.01%)
Aurinia Issues Letter to Shareholders

--Notes recent Board refreshment, deep expertise in drug commercialization

AUPH : 5.88 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.02
1st Resistance Point 5.95
Last Price 5.88
1st Support Level 5.82
2nd Support Level 5.76

See More

52-Week High 7.85
Fibonacci 61.8% 6.78
Fibonacci 50% 6.45
Fibonacci 38.2% 6.13
Last Price 5.88
52-Week Low 5.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar